Vital Therapies, Inc. (VTL) Announces Earnings Results
Vital Therapies, Inc. (NASDAQ:VTL) announced its quarterly earnings results on Wednesday. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02, Bloomberg Earnings reports. During the same period in the prior year, the firm earned ($0.32) earnings per share.
Shares of Vital Therapies (NASDAQ:VTL) traded down 2.78% during mid-day trading on Thursday, hitting $5.25. The stock had a trading volume of 120,379 shares. The firm’s market cap is $221.59 million. The stock has a 50 day moving average price of $5.00 and a 200 day moving average price of $3.59. Vital Therapies has a 52 week low of $2.25 and a 52 week high of $6.50.
A number of brokerages have weighed in on VTL. ValuEngine upgraded Vital Therapies from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 21st. Zacks Investment Research cut Vital Therapies from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. Finally, BidaskClub upgraded Vital Therapies from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 5th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $8.00.
In other Vital Therapies news, Director Jean Jacques Bienaime purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The shares were bought at an average price of $4.00 per share, for a total transaction of $40,000.00. Following the purchase, the director now owns 65,119 shares in the company, valued at approximately $260,476. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Muneer A. Satter purchased 50,000 shares of the firm’s stock in a transaction dated Friday, September 8th. The stock was acquired at an average price of $3.53 per share, for a total transaction of $176,500.00. The disclosure for this purchase can be found here. In the last quarter, insiders bought 190,000 shares of company stock worth $737,800. Corporate insiders own 32.60% of the company’s stock.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Stock Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related stocks with our FREE daily email newsletter.